Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns. Gerhardt Attard, MD, PhD, FRCP, a ...

Shares of Amplitude have rallied after an excellent recent Q1 earnings, yet the stock remains widely undervalued relative to peers. The company raised its full year growth outlook in a tough macro, ...

Amplitude stock fell slightly after its Q4 earnings print, creating a well-timed buying opportunity. The company is expecting revenue acceleration in FY25, driven by improving retention and churn ...

SAN FRANCISCO--(BUSINESS WIRE)--Today Amplitude (Nasdaq: AMPL), the leading digital analytics platform, announced the launch of Guides and Surveys to help organizations improve onboarding and user ...

Center of Ultra-Precision Optoelectronic Instrument Engineering, Harbin Institute of Technology, Harbin 150080, China Key Lab of Ultra-Precision Intelligent Instrumentation (Harbin Institute of ...

Centre for Applied Research in Electronics, Indian Institute of Technology Delhi, Delhi 110016, India ...

Emerging, data-intensive technologies like artificial intelligence and machine learning are gaining popularity. Data centers, which act as the essential infrastructure for these technologies, need to ...

SEATTLE--(BUSINESS WIRE)--LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code ...